Assessment of blood-brain barrier permeability
This test enables quantification of albumin concentration in spinal fluid by nephelometry. A standalone spinal fluid albumin concentration has limited clinical utility; it may provide a general assessment of intactness of the blood-brain barrier.
Nephelometry
Albumin, cerebrospinal fluid
Cerebrospinal fluid albumin
Albumin, spinal fluid
Spinal fluid albumin
CSF
The SFIG / Cerebrospinal Fluid IgG Index Profile, Serum and Spinal Fluid, in conjunction with OLIG / Oligoclonal Banding, Serum and Spinal Fluid is the recommended test for evaluation of multiple sclerosis.
Specimen Type: Spinal fluid
Container/Tube: Sterile vial
Specimen Volume: 1 mL
Collection Instructions: Label specimen as spinal fluid.
0.5 mL
Gross hemolysis | OK |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
CSF | Refrigerated (preferred) | 28 days | |
Frozen | 28 days | ||
Ambient | 14 days |
Assessment of blood-brain barrier permeability
Elevated albumin concentration in spinal fluid may serve as an indicator of the permeability status of the blood-brain barrier. Comparison to an ALB / Albumin, Serum concentration is recommended.
0.0-27.0 mg/dL
Elevated albumin concentrations may be observed in patients with a compromised blood-brain barrier.
Cerebrospinal fluid albumin has limited utility as a standalone test.
Schliep G, Felgenhauer K. Serum-CSF protein gradients, the blood-GSF barrier and the local immune response. J Neurol. 1978;218(2):77-96
The cerebrospinal fluid albumin is determined by immunonephelometry on a Siemens Nephelometer II. In this assay, the light scattered onto the antigen-antibody complexes is measured. The intensity of the measured scattered light is proportional to the amount of antigen-antibody complexes in the sample under certain conditions. If the antibody volume is kept constant, the signal behaves proportionally to the antigen volume. A reference curve is generated by a standard with a known antigen content on which the scattered light signals of the samples can be evaluated and calculated as an antigen concentration. Antigen-antibody complexes are formed when a sample containing antigen and the corresponding antiserum are put into a cuvette. A light beam is generated with a light emitting diode, which is transmitted through the cuvette. The light is scattered onto the immuno-complexes that are present. Antigen and antibody are mixed in the initial measurement, but no complex is yet formed. An antigen-antibody complex is formed in the final measurement. The result is calculated by subtracting the value of the final measurement from the initial measurement. The distribution of intensity of the scattered light depends on the ratio of the particle size of the antigen-antibody complexes to the radiated wavelength.(Instruction manual: Siemens Nephelometer II. Siemens, Inc; Version 2.3, 2008; Addendum to the Instruction Manual 2.3, 08/2017)
Monday through Friday
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
82042
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
ALBSF | Albumin, CSF | 1746-7 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
ALBSF | Albumin, CSF | 1746-7 |